Valion Bio, Inc. (VBIO)
Valion Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Antonio, TX, US. The stock last traded at $0.24, down 21.45% on the session, giving a market capitalisation of $1.0M. On trailing twelve-month figures it carries a trailing P/E of -8.12, a net margin of -145.6%. Its beta of 1.83 implies it has historically moved more than the broad market.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Valion Bio, Inc. is most often compared with the following Healthcare names: